ArticleClinical case reports2025
Lymphoma Induced Chylothorax Complicated by Disseminated Histoplasmosis and Esophagopericardial Fistula.
Article in Clinical case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Lymphoma Induced Chylothorax Complicated by Disseminated Histoplasmosis and Esophagopericardial Fistula.Clinical case reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This case report highlights the need to consider both infection and malignancy in the differential of a chylothorax, particularly in an immunosuppressed patient. The case demonstrates the challenges in treating a chylothorax, both in terms of appropriate drainage and the necessity to maintain a low-fat diet. The case also presented challenges in treating histoplasmosis, both in terms of renal effects of amphotericin B and the effect of a low-fat diet on an oral antifungal agent. Although infection may be controlled with appropriate antifungal agents, the underlying hematologic malignancy must be controlled in order to successfully treat the patient.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.